Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 5
- 主要终点
- Tumor Volume
研究概览
简要总结
The study consists in only one treatment group, which will receive the first-line therapy for the disease - standard radiotherapy and a 150 mg/m2 dose of the investigational product (nimotuzumab)
详细描述
General Purpose
- To determine the therapeutic efficacy of the treatment with nimotuzumab in combination with radiotherapy in pediatric patients with diffuse intrinsic astrocytic of the brainstem glioma
Specific Purposes
- To determine the efficacy regarding the event-free survival (EFS) rate by 6 months of treatment.
- To determine the overall survival time of the patients with diffuse intrinsic astrocytic tumors of the cerebral trunk treated with combined radiotherapy and nimotuzumab.
- To determine the antitumoral objective response of the patients treated with combined radiotherapy and nimotuzumab.
- To determine the duration time of the response in the cases of objective response reached (CR or PR) or disease stabilization.
- To assess the toxicity of the combination AcM h-R3-nimotuzumab and radiotherapy in the patients enrolled in the clinical study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pediatric patients with diffuse intrinsic brainstem gliomas, documented by standard imaging techniques (MRI). Note: Tumor biopsy and histological confirmation are not required in this study.
- •Patients eligible for radiotherapy with Cobalt
- •The patients should not have received a previous specific oncological treatment.
- •Aged > 3 years old < 18 years old
- •Patients with measurable lesions, defined as those that can be accurately measured in at least 2 dimensions (the 2 largest perpendicular diameters), using standard techniques (MRI).
- •Female patients with childbearing potential should present a negative pregnancy test and adopt effective birth control methods, in case they are sexually active.
- •Male patients who can father a child should adopt effective birth control methods, in case they are sexually active.
- •Life expectancy > 12 weeks
- •Health general status, according to Karnofsky Index > 40% (Karnofsky Index for patients > 16 years old), Lansky > 40% (for patients < 16 years old)
- •Laboratory parameters within the normal limits, defined as: Hematopoietic: Hemoglobin > 10 g/L, Total Leukocytes > 2 x 109 cells/L, Platelets > 100 x 109/L; Hepatic: Liver functioning within the normal limits and without hepatic diseases demonstrated by ALT, AST < 2.5 x above the reference value and Total Bilirubin < 1.5 x above the reference value; Renal function: Serum Creatinine < 1.5 x above the reference value.
- •The parents or legal guardians should express, voluntarily, in writing, that the patient will be enrolled in the study upon signature of the informed consent form. At the investigator's discretion, where applicable, the consent will be obtained from the minor.
排除标准
- •Low-grade brainstem glioma (e.g., focal, cervicomedullary, tectal brainstem glioma).
- •Patients previously treated with some AcM.
- •Patients previously treated with some antineoplastic therapy, including chemotherapy, immunotherapy or radiotherapy.
- •Concurrent treatment with some antineoplastic therapy not conceived in the study protocol.
- •Breastfeeding or pregnant patients.
- •Patients that, at the time of enrollment, have some related chronic disease under decompensation (e.g., cardiopathy, diabetes, hypertension).
- •Patients who have history of hypersensitivity to this or another similar product.
- •Fever, severe septic processes and/or severe or acute allergy.
- •Patients who are participating in another clinical study with therapeutic purposes for their disease based on the time of the study enrollment.
- •Presence of a second tumor.
研究组 & 干预措施
Nimotuzumab
The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
干预措施: Radiotherapy (Radiation)
Nimotuzumab
The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
干预措施: Nimotuzumab (Biological)
结局指标
主要结局
Tumor Volume
时间窗: 6 months
A Magnetic Resonance Imaging (MRI) will be used for measuring the tumor volume and it will be performed before the enrollment in the clinical study and every 12 weeks. The patient follow-up will be performed for 2 years after his/her inclusion in the investigation. The final evaluation will be performed 2 years after the inclusion of the last patient. The main response variable will be the progression-free survival by 6 months.
次要结局
未报告次要终点